EP1565200A4 - Nucleic acid corresponding protein entitled 24p4c12 useful in treatment and detection of cancer - Google Patents

Nucleic acid corresponding protein entitled 24p4c12 useful in treatment and detection of cancer

Info

Publication number
EP1565200A4
EP1565200A4 EP02789937A EP02789937A EP1565200A4 EP 1565200 A4 EP1565200 A4 EP 1565200A4 EP 02789937 A EP02789937 A EP 02789937A EP 02789937 A EP02789937 A EP 02789937A EP 1565200 A4 EP1565200 A4 EP 1565200A4
Authority
EP
European Patent Office
Prior art keywords
cancer
useful
detection
treatment
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02789937A
Other languages
German (de)
French (fr)
Other versions
EP1565200A2 (en
Inventor
Arthur B Raitano
Karen Jane Meyrick Morrison
Wangmao Ge
Pia M Challita-Eid
Aya Jakobovits
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agensys Inc
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Publication of EP1565200A2 publication Critical patent/EP1565200A2/en
Publication of EP1565200A4 publication Critical patent/EP1565200A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP02789937A 2002-11-27 2002-11-27 Nucleic acid corresponding protein entitled 24p4c12 useful in treatment and detection of cancer Withdrawn EP1565200A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/038264 WO2004050828A2 (en) 2002-11-27 2002-11-27 Nucleic acid corresponding protein entitled 24p4c12 useful in treatment and detection of cancer

Publications (2)

Publication Number Publication Date
EP1565200A2 EP1565200A2 (en) 2005-08-24
EP1565200A4 true EP1565200A4 (en) 2009-06-24

Family

ID=32467113

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02789937A Withdrawn EP1565200A4 (en) 2002-11-27 2002-11-27 Nucleic acid corresponding protein entitled 24p4c12 useful in treatment and detection of cancer

Country Status (6)

Country Link
EP (1) EP1565200A4 (en)
JP (1) JP2006508163A (en)
AU (3) AU2002352976B2 (en)
CA (1) CA2503346C (en)
IL (1) IL167892A (en)
WO (1) WO2004050828A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2185574E (en) * 2007-09-07 2013-08-26 Agensys Inc Antibodies and related molecules that bind to 24p4c12 proteins
CA2754531A1 (en) * 2009-03-06 2010-09-30 Seattle Genetics, Inc. Antibody drug conjugates (adc) that bind to 24p4c12 proteins
JP2013049646A (en) * 2011-08-30 2013-03-14 Tokyo Medical Univ Cancer therapeutic agent
US20180282383A1 (en) 2015-10-02 2018-10-04 University Of Copenhagen Small molecules blocking histone reader domains
US11513127B2 (en) 2016-01-25 2022-11-29 Genentech, Inc. Methods for assaying T-cell dependent bispecific antibodies
WO2018199341A1 (en) * 2017-04-28 2018-11-01 学校法人藤田学園 Allergy antigen and epitope for same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061746A1 (en) * 1999-04-12 2000-10-19 Agensys, Inc. 13 transmembrane protein expressed in prostate cancer
WO2001046258A2 (en) * 1999-12-23 2001-06-28 Incyte Genomics, Inc. Transporters and ion channels

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ATE157012T1 (en) 1989-11-03 1997-09-15 Univ Vanderbilt METHOD FOR THE IN VIVO ADMINISTRATION OF FUNCTIONAL FOREIGN GENES
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
SE9002480D0 (en) 1990-07-23 1990-07-23 Hans Lilja ASSAY OF FREE AND COMPLEXED PROSTATE-SPECIFIC ANTIGEN
WO1993025673A1 (en) 1992-06-04 1993-12-23 The Regents Of The University Of California In vivo gene therapy with intron-free sequence of interest
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
PT735893E (en) 1993-09-14 2009-03-06 Pharmexa Inc Pan dr-binding peptides for enhancement of the immune response
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5919652A (en) 1994-11-09 1999-07-06 The Regents Of The University Of California Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
CU22559A1 (en) 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech EXPRESSION SYSTEM OF HETEROLOGICAL ANTIGENS IN E. COLI AS FUSION PROTEINS
ATE511849T1 (en) 1996-03-11 2011-06-15 Epimmune Inc PEPTIDES WITH INCREASED BINDING AFFINITY FOR AT LEAST THREE HLA-A3-LIKE MOLECULES
WO1998004720A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
US5840501A (en) 1996-10-25 1998-11-24 Bayer Corporation Determination of cPSA
WO1999006550A2 (en) * 1997-08-01 1999-02-11 Genset 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN PROSTATE
US6943235B1 (en) * 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061746A1 (en) * 1999-04-12 2000-10-19 Agensys, Inc. 13 transmembrane protein expressed in prostate cancer
WO2001046258A2 (en) * 1999-12-23 2001-06-28 Incyte Genomics, Inc. Transporters and ion channels

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2004050828A2 *

Also Published As

Publication number Publication date
AU2008200628A1 (en) 2008-03-06
CA2503346A1 (en) 2004-06-17
EP1565200A2 (en) 2005-08-24
AU2009208065A1 (en) 2009-08-27
WO2004050828A3 (en) 2004-12-09
AU2002352976B2 (en) 2007-11-08
JP2006508163A (en) 2006-03-09
CA2503346C (en) 2014-03-18
WO2004050828A2 (en) 2004-06-17
AU2008200628B2 (en) 2009-05-07
AU2002352976A1 (en) 2004-06-23
IL167892A (en) 2012-06-28
AU2009208065B2 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
EP1572916A4 (en) Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer
AU2003243151A8 (en) Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
HK1152714A1 (en) Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer steap-1
EP1537140A4 (en) Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer
AU2002318112B2 (en) Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
EP1517606A4 (en) Nucleic acid and corresponding protein entitled 193p1e1b useful in treatment and detection of cancer
EP1622571A4 (en) Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer
PT1537140E (en) Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer
EP1372719A4 (en) Nucleic acid and corresponding protein entitled 125p5c8 useful in treatment and detection of cancer
EP1590437A4 (en) Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
EP1409710A4 (en) Nucleic acid and corresponding protein entitled 161p5c5 useful in treatment and detection of cancer
AU2002246708A1 (en) Nucleic acid and encoded zinc transporter protein entitled 108p5h8 useful in treatment and detection of cancer
AU2001285018A1 (en) Nucleic acids and corresponding proteins entitled 83p2h3 and catrf2e11 useful in treatment and detection of cancer
EP1565200A4 (en) Nucleic acid corresponding protein entitled 24p4c12 useful in treatment and detection of cancer
EP1578980A4 (en) Nucleic acid and corresponding protein entitled 213p1f11 useful in treatment and detection of cancer
AU2003268355A8 (en) Localization of human cytomegalovirus nucleic acids and proteins in human cancer cells
EP1539805A4 (en) Nucleic acids and corresponsing proteins entitled 101p3a11 or phor-1 useful in treatment and detection of cancer
EP1545556A4 (en) Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer
EP1399174A4 (en) Nucleic acid and corresponding protein entitled 121p1f1 useful in treatment and detection of cancer
EP1499350A4 (en) Nucleic acid and corresponding protein entitled 205p1b5 useful in treatment and detection of cancer
IL164390A0 (en) Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer
ZA200501838B (en) Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
AU2001286541A1 (en) Nucleic acids and corresponding proteins entitled phor1-a11 and phor1-f5d6 useful in treatment and detection of cancer
AU2002305170A1 (en) Nucleic acid and corresponding protein entitled 151p3d4 useful in treatment and detection of cancer
AU2012244341A1 (en) Nucleic acids and corresponding proteins entitled 191P4D12(b) useful in treatment and detection of cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050421

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20090525

17Q First examination report despatched

Effective date: 20090923

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AGENSYS, INC.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150304

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150715